Phaseline

Targets › PCSK9

PCSK9 (Proprotein convertase subtilisin/kexin type 9): drug programs, companies and trials

20 programs from 20 companies in 69 trials: 25 Phase 3, 22 Phase 4, 16 Phase 2, 6 Phase 1; Cardiovascular, Metabolic and endocrine, Oncology; next expected readout Nov 2026.

Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. (UniProt, Q8NBP7)

Open in Phaseline: the race on PCSK9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisInclisiran sodium
PCSK9 mRNA rnai inhibitor
PCSK9Phase 4Hypercholesterolaemia; Plaque, Atherosclerotic; Coronary Heart Disease; Coronary Artery Disease …Nov 2026
First Affiliated Hospital of Xinjiang Medical UniversityPCSK9 inhibitors
PCSK9 inhibitor
PCSK9Phase 4Coronary Artery DiseaseDec 2026
University Medical Centre LjubljanaInclisiran
PCSK9 mRNA RNAi inhibitor
PCSK9Phase 4HypercholesterolemiaMay 2027
AmgenEvolocumab
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 4Cardiovascular DiseaseMay 2027
Peking Union Medical College HospitalRecaticimab
PCSK9 inhibitor (monoclonal antibody)
PCSK9Phase 4Intracranial AtherosclerosisDec 2027
Instituto de Investigación Marqués de ValdecillaPCSK9 inhibitors
PCSK9 inhibitor
PCSK9Phase 4Rheumatoid Arthritis (RA)Apr 2031
Merck & Co. (MSD)Enlicitide Decanoate (MK-0616)
PCSK9 inhibitor
PCSK9Phase 3Hyperlipidemia; Hypercholesterolemia; Arteriosclerosis; Lipoprotein(a) …Dec 2026
AstraZenecaAZD0780
PCSK9 inhibitor
PCSK9Phase 3Heterozygous Familial Hypercholesterolaemia; Cardiovascular Disease; DyslipidaemiaJan 2027
Innovent Biologics (Suzhou)Tafolecimab (IBI306)
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 3Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia; Acute Coronary Syndrome; Lung Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) …Feb 2027
Shanghai East HospitalRecaticimab
PCSK9 inhibitor
PCSK9Phase 3StrokeMar 2027
Beijing Anzhen HospitalTafolecimab
PCSK9 inhibitor
PCSK9Phase 3Aortic StenosisDec 2027
Icahn School of Medicine at Mount SinaiInclisiran
PCSK9 mRNA RNAi inhibitor
PCSK9Phase 3Atherosclerotic Cardiovascular DiseaseJun 2032
University of OxfordInclisiran
PCSK9 mRNA RNAi inhibitor
PCSK9Phase 3Atherosclerotic Cardiovascular DiseaseDec 2049
Hasten BiopharmaceuticalLerodalcibep (HST101)
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 3Hypercholesterolemia–
NewAmsterdam Pharmaevolocumab
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 2Dyslipidemias; Type 1 Diabetes; Stroke, Ischemic; STEMI - ST Elevation Myocardial Infarction …Nov 2026
Regeneron PharmaceuticalsAlirocumab
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 2Hypercholesterolemia; Dyslipidemias; Early PCSK9 Inhibitor on Ventricular Remodling; Acute Myocardial Infarction …Dec 2026
Beijing Chest Hospital, Capital Medical UniversityRecaticimab
PCSK9 inhibitor
PCSK9Phase 2Non Small Cell Lung CancerMar 2027
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTafolecimab
PCSK9-targeting monoclonal antibody
PCSK9Phase 2Bladder Urothelial CarcinomaJun 2028
Verve TherapeuticsVERVE-102
Base-editing technology designed to disrupt PCSK9 gene expression in the liver
PCSK9Phase 1Heterozygous Familial HypercholesterolemiaOct 2027
Monash UniversitySTX-1150
mRNA-guided epigenome modulation targeting PCSK9 to reduce LDL-C
PCSK9Phase 1Elevated LDL-C and High CholesterolDec 2028

Conditions

Hypercholesterolemia (6) Atherosclerotic Cardiovascular Disease (4) Coronary Artery Disease (3) Cardiovascular Disease (3) Dyslipidemias (3) Aortic Stenosis (3) Hypercholesterolaemia (2) Acute Coronary Syndrome (2) Dyslipidaemia (2) Non Small Cell Lung Cancer (2) Hyperlipidemia (2) Healthy (2)

Modalities

small molecule (7), mixed (5), other (3), antibody (3), protein or peptide (2)

Companies

Novartis (1) AstraZeneca (1) Shanghai East Hospital (1) First Affiliated Hospital of Xinjiang Medical University (1) Monash University (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Instituto de Investigación Marqués de Valdecilla (1) NewAmsterdam Pharma (1) Verve Therapeutics (1) Beijing Chest Hospital, Capital Medical University (1) Amgen (1) University of Oxford (1) Beijing Anzhen Hospital (1) Merck & Co. (MSD) (1) Icahn School of Medicine at Mount Sinai (1) Innovent Biologics (Suzhou) (1) Hasten Biopharmaceutical (1) University Medical Centre Ljubljana (1) Peking Union Medical College Hospital (1) Regeneron Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.